SignalChem Initiates Phase 1 Clinical Trial for SLC-391 in Subjects with Solid TumoursContinue Reading
VANCOUVER, BRITISH COLUMBIA-(November 7, 2019) - SignalChem Lifesciences Corp. ("SLC"), a clinical stage biotech company, has dosed its first patient in a Phase 1 clinical trial studying the safety and tolerability of SLC-391, a potent and selective AXL inhibitor, at Princess Margaret Cancer Centre in Toronto, Ontario. The study marks a significant clinical milestone for SLC. By taking a targeted therapy approach, the Company aims to develop SLC-391 for the treatment of various forms of cancer.
AXL is a putative driver of diverse cellular processes that are critical for the development, growth, and spread of tumours, including proliferation, invasiveness and migration, epithelial-mesenchymal transition (EMT), stemness, angiogenesis, and immune modulation. It has also been associated with both intrinsic and acquired resistance to chemotherapeutic drugs (e.g, paclitaxel and cisplatin) and molecularly targeted therapies (e.g, erlotinib and gefitinib). AXL has emerged as an increasingly attractive target for anticancer therapies in recent years. SLC-391 is a novel, potent and specific small molecule AXL inhibitor. It has demonstrated antiproliferative activity against different tumour cell lines in vitro and established efficacy in different animal models including non-small cell lung carcinoma (NSCLC), chronic myeloid leukemia (CML) and acute myeloid leukemia (AML) models. It can also work with other approved targeted therapies synergistically in different animal models to potentiate anti-tumour activity.
"Targeting receptor tyrosine kinase AXL represents a promising new approach for treating cancers, especially for cancer metastases, cancer stem cell survival, and acquired resistance to chemotherapies and other targeted therapeutics. SLC has developed its potent, selective and orally bioavailable Axl inhibitor SLC-391 to meet these medical needs. This novel therapy could provide a meaningful and beneficial alternative to cancer patients", commented by Mr. Jun Yan, the CEO and founder of SLC.
About the Phase 1 Trial
The Phase 1 trial is an open-label, dose-escalation, and dose-expansion study of the safety and pharmacokinetics of the AXL Inhibitor SLC-391 administered orally to subjects with solid tumours. The study is being conducted with sites located at The Ottawa Hospital Cancer Centre in Ottawa, Ontario, Princess Margaret Cancer Centre in Toronto, Ontario, and Juravinski Cancer Centre in Hamilton, Ontario. The primary objectives are to evaluate the safety of oral SLC-391 and to determine the maximum tolerated dose (MTD) of SLC-391. The secondary objectives are to characterize the pharmacokinetic (PK) profile of SLC-391, to determine the recommended phase 2 dose (RP2D) of SLC-391 and to preliminarily evaluate the efficacy of SLC-391. For more information about this clinical trial, please visit https://clinicaltrials.gov/ct2/show/NCT03990454.
SLC-391 is a potent, selective and orally bioavailable small molecule Axl inhibitor. Currently, the phase I clinical trial to evaluate the safety and tolerability of SLC-391 in cancer patients with solid tumour is on-going in Canada.
SignalChem Lifesciences Corporation (“SLC”), headquartered in British Columbia, Canada, is a clinical-stage company developing novel targeted therapies for oncology. Its unique business model has been built upon two important pillars: the Bioreagents and Research Services business and the Drug Discovery and Development business. A group of scientists with extraordinary expertise and experience in kinase biology and drug discovery are working together cohesively to provide the best products and services to its customers around the world and to maximize the efficiency of its drug discovery efforts. For more information, please visit www.signalchemlifesciences.com.
Forward-Looking Statements and Information
This release contains forward-looking statements that are not based on historical facts. These forward-looking statements involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied. Readers are cautioned not to place undue reliance on such forward-looking statements.
Zaihui Zhang, PhD
CSO, VP R & D
Signalchem Lifesciences Corp.
+ 604 232 4600 ext. 114